Research & Reviews: Journal of Clinical and Medical Case Studies

The Availability and Absorption Characteristics of a Healthy Dose of Recombinant Human Growth Hormone (GH) Delivered Subcutaneously in Adults with GH Deficiency

Hari Prasad Sonwani[1]*, Aakanksha Sinha[2]

[1]Department of Pharmacy, Apollo College of Pharmacy, Durg, Chhattisgarh, India

[2]Department of Pharmacy, University Institute of Pharmacy, Raipur, Chhattisgarh, India

Review Article

Received: 13-Nov-2023, Manuscript No. JCMCS-23-119899; **Editor assigned:** 15-Nov-2023, PreQC No. JCMCS-23-119899 (PQ); **Reviewed:** 29-Nov-2023, QC No. JCMCS-23-119899; **Revised:** 22-Jan-2025, Manuscript No. JCMCS-23-119899 (R); **Published:** 29-Jan-2025, DOI: 10.4172/JCMCS.10.1.001

***For Correspondence:** Hari Prasad Sonwani, Department of Pharmacy, Apollo College of Pharmacy, Durg, C.G, India;
E-mail: harisonwani10@gmail.com

Citation: Sonwani HP, et al. The Availability and Absorption Characteristics of a Healthy Dose of Recombinant Human Growth Hormone (GH) Delivered Subcutaneously in Adults with GH Deficiency. RRJ Clin Med Case Stud. 2025;10:001.

ABSTRACT

Goals: In females with GH Deficiency (GHD), to examine the absorption profile and calculate the bioavailability of three doses of recombinant human Growth Hormone (rhGH) less than 2 IU. Comparing the mean 24-hour GH concentrations following s.c. rhGH injection to the physiological mean 24-hour GH concentration of healthy females of similar age, height, and BMI was the study's second goal. Techniques The study included 14 female patients with substituted GHD and 14 healthy females with similar BMI, height, and age. Following an intraperitoneal injection of rhGH at dosages of 0.6, 1.2, or 1.8 IU, all GHD patients had a 24-hour GH sample. Furthermore, these individuals received an intravenous injection of rhGH (1 IU) followed by a 4-hour GH sampling. When well For a 24-hour period, patients' blood was collected every 10 minutes to ascertain their physiological GH profile.

Outcomes: A mean and maximum GH concentration of 0.95 ± 0.04 mU l^{-1} and 2.62 ± 0.09 mU l^{-1} were obtained with a single 0.6 IU s.c. dosage. The mean and maximum GH levels doubled (or tripled) in response to a doubling (or tripling) of the rhGH dose. The average time to attain the highest concentration of GH was 261 ± 27 minutes. After receiving a single-dose 1.2 IU of growth hormone, the mean concentration of GH in healthy females was found to be similar. The S.C. administered dose's mean availability was 63% ± 4%.

Conclusion: When 1.2 IU was administered, the mean GH concentration in healthy females was found to be similar to the mean physiological GH concentration similar BMI, age, and height.

Keywords: GH; GH deficiency; Somatotropin; Adults; Absorption

INTRODUCTION

Several clinical trials were created to account for side effects with the advent of recombinant human growth hormone, which was employed in later research and led to a drop in the incidence of hormone (rhGH) and a smaller increase in serum levels of IGF-I (although supranormal levels were still detected) [1]. As of right now, the recommendation for adults with Growth Hormone Deficiency (GHD) is to begin therapy at a dose of ± 0.6 GH based on the findings of our lab and others that investigate the impact of GH replacement. It has IU day^{-1}, and after three to four weeks, customize this dosage show that GH therapy is helpful up until normal serum IGF-I concentrations are reached. It is impacts on bone, quality of life, and body composition It seems that doses less than 2 IU day^{-1} are frequently able to do mass in GHD-affected adults [2-5]. Initial research on serum IGF-I concentrations normalized by growth hormone [3-7]. replacement in GHD people who took high doses of GH every day Despite the fact that numerous researchers examined the absorption dosages (about 5 IU day^{-1}) according to pediatric experience profile of Subcutaneous (S.C.) injected human growth hormone in adults [8]. Due to the high frequency of adverse effects, which are primarily associated with GH Deficiency (GHD), there are no data on the fluid retention), elevated levels of IGF-I in the serum, and the absorption characteristics of dosages less than 2 IU day^{-1} [9–12]. Simply that this dosage might have been excessive for adults. We examine the absorption characteristics of in this study Three separate rhGH doses (0.6, 1.2, and 1.8 IU) that are all less than 2 IU. Furthermore, mean GH concentrations in female GHD patients following subcutaneous injection are contrasted with females with same BMI, height, and age using GHD. Lower dosages (about 2.5 IU day^{-1}) were.
Information on the accessibility of subcutaneously delivered rhGH injections was obtained by skinfold injection at the midthigh scarce. Using a 13 mm 29G needle, Jorgensen et al level based on infusion studies [13]. When rhGH was administered, the dose of reported a lower steady state concentration of GH was 0.6, 1.2, or 1.8 IU, according to the I.V. infusion was randomized at a baseline of genetropin 4 IU ml^{-1}, while the S.C. infusion was indicating that S.C. given GH will degrade locally. Pharmacia and Upjohn, peptide hormones; international the bioavailability of rhGH in a very small amount (1 mg=3 IU) in Reference Preparation (IRP) 88/624. 50%–70% was the high dose [14]. Another objective of the patients was permitted to drink during the research. This investigation was thus to calculate the accessibility of hospital standard meals and moderate exercise Three S.C. given doses of rhGH were permitted range of the adult GHD substitute dosage.

LITERATURE REVIEW

Several factors were used to define the absorption pattern of the 24-hour absorption study: C_{max}: The highest GH concentration ever measured following subjects receive an s.c. rhGH injection The study included 14 female patients with GH deficit (GHD) and 14 female healthy controls. During insulin-induced hypoglycemia, the peak serum growth hormone response was less than 1.3 mU l^{-1} in all patients. Thirteen patients (eleven owing to pituitary adenomas, one patient owing to a pituitary tumor, and one patient owing to a germinoma) experienced adult-onset GHD. One patient had childhood-onset GHD because of the Sheehan syndrome). Together with GHD, the following conditions were present in 1 patient: Deficiency in LH/FSH, deficiency in LH/FSH and TSH, deficiency in LH/FSH and ACTH, complete anterior pituitary gland failure in 7 individuals, and total pituitary gland failure in 2 cases. With the exception of two elderly patients receiving oxygen replacement therapy, all patients received conventional substitution treatment when necessary. All subjects provided verbal informed consent, and the Leiden University Medical Center's ethics committee authorized the study.
Layout of the research: t_{max}: The moment when C_{max} occurs.
AUC: The linear trapezoidal method's calculation of the area under the curve.
Average concentration: average 24-hour GH level following injectable rhGH S.C.
IV boluses Individuals were sighted in following an overnight fast and skipping the recommended S.C. GH dosage from the previous evening in the outpatient clinic. After drawing a baseline blood sample, an intravenous injection of 1 IU (Genotropin 4 IU ml^{-1}, Pharmacia and Upjohn, peptide hormones; IRP 88/624) of rhGH was administered. Every 4 minutes for 20 minutes, every 5 minutes for the next 40 minutes, and every 15 minutes for an additional three hours was blood drawn. The trapezoidal method was used to calculate the AUC Hourly profiles Blood was drawn from 14 healthy participants every 10 minutes for 24 hours, beginning at 9:00 a.m. Patients were permitted to partake in routine hospital meals and engage in modest physical activity during the research Every female with GHD was assigned at random to either Assessment of the accessibility The three dose groups of rhGH availability (0.6, 1.2, or 1.8 IU day^{-1}) were assessed by comparing the individual AUC following injection, with the latter being the proportion of injected rhGH absorbed in the circulation, obtained in one or two steps of 0.6 IU, respectively. Because these patients were chosen from a study population, the distribution of these 14 patients among compensating for the variation in dose was based on the S.C. injection with the AUC following the I.V. bolus after 60 patients the dosage groups were not equivalent: patients 3, 6, and 5 in the day-1 group: 0.6, 1.2, and 1.8 IU, respectively. Composition

of body with the least amount of clothing, weight Following a six-month course of therapy, each patient was measured to the closest 0.1 lbs. Frequent GH sample was used to measure height to the closest 0.001 meter following both Intravenous (I.V.) procedures. Bolus injection and subcutaneous rhGH injection were used to calculate BMI. Furthermore, mass (kg)/height $(m)^2$. By measuring body composition, the surface area of the body was computed. The equation that Du Bois created [15]. body resistance from a broader sample of 19 female control analyzers, 14 healthy girls with similar age and Human-IM Scan impedance BMI were chosen (Dietosystem, Milan, Italy). The population estimate, or TBW, was based on a 24-hour GH profile. According to impedance at 100 kHz and body height. For a thorough explanation, see Janssen et al [16]. 24-hour absorption analysis An IV catheter was inserted within time-resolved immunofluorescence measurement of GH in a forearm vein at 20.15 hours following the completion of the assays makeup of the body (see below). The 30-minute fluorescence assay (Wallac, Turku, Finland) blood sample is intended specifically for 24 hour intervals began at 2:00 a.m. the 22 kiloDalton GH protein at 21.15 hours. Human standards applied.

Biosynthetic GH (Pharmacia AB, Sweden) was calibrated using the WHO First IRP 80-505 (1 mg=2.6 IU) and diluted in bovine calf serum. The assay's intra-assay coefficient of variation was less than 8.4%, and its detection limit was 0.03 mU l^{-1} (=0.012 mg l^{-1}). In one healthy control, 3% of the GH readings were below the extremely low detection limit of 0.03 mU l^{-1}. The detection limit was set for them. Throughout the 24-hour investigation, the GH concentrations of all other subjects were measurable. Following purification and extraction on ODS-silica columns, the total serum IGF-I concentration was measured by RIA (Incstar, Stillwater, MN). The variation between the assays was less than 11%. The limit of detection was 1.5 nmol l^{-1} (Figure 1).

Figure 1. (a) Mean (+1 s.d.) physiological 24 h GH profile of 14 healthy subjects and (b) Mean (+1 s.d.) 24 h GH profile after Age, height, and BMI of the females with GHD were injected rhGH in females with GH deficiency.



Figures: SPSS for Windows was used to conduct the statistical analysis (version 7.0, SPSS, Chicago, IL). The outcomes are stated as the mean ± s.e. mean, excepting special circumstances. Pearson's Correlations were computed using the correlation coefficient ANOVA was utilized to examine the impact of the dosage on the properties of kinetics. Utilizing the student's t-test, compare the findings of the S.C. research to those of the 24-hour profile among subjects in good health. Disparities were taken into account noteworthy at $P<0.05$. Three subcutaneous doses ($: 0.6 IU: 1.2 IU; and: 1.8 IU) were.

RESULTS AND DISCUSSION

Females with GH insufficiency received rhGH injections based on their age, height, and body mass index (b) Not appreciably different from the healthy control group. (Height: 166.7 ± 2.1 and 44 ± 3 years; age: BMI: 25.5 ± 1.0 and 23.3 ± 0.9 kg m^{-2}, respectively; 164.4 ± 2.6 cm; P=0.001 and 0.004, respectively. Nothing noteworthy in healthy controls and GHD females, in that order). After adjusting for dosage, the differences were discovered (95% CI: 14 healthy girls' mean 24-hour GH profile is displayed in AUC/S.C. dosage, 2.1–2.5, 1.9–2.9, and 1.6–3.2: P=0.958. The 24-hour profile following a single-dose C_{max}/S.C. dose is displayed. P=0.942 for administering rhGH injections to GHD individuals. Average GH low, average and high dosage, correspondingly), showing that concentrations following S.C. injection of rhGH were within a dose doubling (or tripling) the range of the maximal GH concentration following S.C. and the mean GH concentration in a healthy AUC women, with the exception of one patient (interval 0.85–4.00 and injection). 261 ± 27 minutes after the S.C. injection was the t_{max} 0.75–3.40 mU l^{-1}, in both healthy controls and GHD patients No discernible variations in t_{max} could be found correspondingly). The mean GH in female GHD patients varied between dosage groups (P=0.284) concentration following a 1.2 IU S.C. injection (95% CI): there was a strong correlation between the GH dose and mean GH. Concentration of 1.54, 2.41 mU l^{-1} (r=0.842; P<0.0005). There was no statistically significant difference in the cartelistic from what is seen in healthy after the dosage was adjusted, a females (95% CI: 1.28, lation coefficient) was discovered.

Total body water (measured by multifrequency) is 2.06 mU l^{-1}, while the mean concentration after 0.6 and 1.8 IU of rhGH, respectively, was substantially less than body surface area (r=0.936, body weight, or BIA P=0.004) and more (95% CI: 0.87, 1.03 mU l^{-1} r=0.924, respectively).

P=0.019; CI: 1.92, 3.98 mU l^{-1}; compared to the average GH Owing to technical issues that arose during the IV bolus research, focus on women in good health. Two of the fourteen patients' outcomes, each randomly assigned. It provides details on the S.C. profiles. 1.8 IU rhGH was not included in the calculation of the. Following the subcutaneous injection, the AUC and C_{max} were available of The injection dose in S.C. Average accessibility of The S.C. administered dose varied significantly amongst the three dosing groups, ranging from 63% (95% CI: 55, 71%).

Serum IGF-I levels following six months of rhGH treatment indicate that mean GH doses of 1.6 IU day^{-1} are required in the low, middle, and high dose groups, respectively, for long-term (2 years) normalization of serum IGF-I levels of 11.9 ± 3.6, 15.8 ± 4.2, and 20.0 ± 2.6 nmol l^{-1}. Adults with GHD should not receive rhGH therapy, and these. A relationship between mean serum GH concentrations and gender was discovered, with females having comparatively greater IGF-I concentration in serum (r=0.383) and centration (1.8 and 1.4 IU day^{-1}, respectively) in males 0.175). Serum IGF-I average in healthy subjects. It's unclear whether the GH's pulpability 20.2 ± 2.0 nmol l^{-1} was found. In healthy controls, secretion is relevant to physiology It has been demonstrated that pulsatile GH injection in rats become more potent than a steady infusion in stimulating.

Approximately

Lengthwise bone growth, body composition, and serum IGF-I mRNA in this work, we looked into how a weight gain is absorbed [17]. In GHD-afflicted adults, temporary serum IGF-I responses were higher (44 hours) following repeated subcutaneous rhGH administration in the thigh. Which, as compared to fewer frequent injections, is in accordance with the guidelines (n=8) intravenous bolus shots with relation to adult and pediatric rhGH therapy. The identical dose of (n=2) intravenous administrations IGF-I serum. The study evaluated three different doses: 0.6, 1.2, and 1.8. Reactions with continuous infusion were as substantial, though Lower than those given in such as those following eight intravenous boluses, IU indicates that the length of research on pharmacokinetics and more according to the increased GH levels can be just as important as pulpability at dose that is now advised, at least temporarily, for individuals with GHD. Nevertheless, this suggestion is at the very beginning of rhGH treatment not in line with the current study's findings. The impacts of 0.6, 1.2, or 1.8 were recently examined because the proportion of plasma samples below a GH For three months, the concentration of 0.1 mU l^{-1} IU of rhGH day^{-1} is higher in healthy females with GHD adults.

The amounts that were administered were determined by comparing the physiological (11.8%) to the substituted GHD patients (0.3% with a data on healthy patients' mean 24-hour GH levels (S.C. dose of 1.2) (data not shown), nevertheless blood IGF-I under the presumption of 60% availability. While not statistically significant, the concentrations were slightly. The range of mean GH concentrations in healthy females is higher in the current study.

These three dosages were similar in terms of the mean range. The study's mean projected availability of rhGH physiological GH concentration in females in good health was 63%, determined by dividing the AUC after similar BMI, height, and age. There was no discernible difference between the AUC and the thigh injection given in the evening between the mean 24-hour GH concentration following intravenous administration (morning) and after accounting for following a 1.2 IU subcutaneous injection and the average physiological variations in the GH dosage. The assessment got to be concentration of GH. 1.2 IU is

thought to be the maximal availability for females with GHD, as several Mean serum IGF-I factors, for which no adjustment is possible, are influenced by rhGH day^{-1} for six months Nonetheless, the concentration was marginally lower (but not the estimated availability). Initially, the mode of entry of substantially) in comparison to that in the healthy control group, the plasma half-life is influenced by GH released into the bloodstream group, suggesting that increased rhGH and consequently GH dosages. With an intravenous bolus, the half-life is shorter Greater mean GH concentrations are required compared to those that occur after GH is infused steadily. Well, it is malign serum levels of IGF-I. According to recent findings, it is probable that the rate of GH metabolic clearance must be. It is believed that for females with GHD, 1.2 IU of GH is the maximum availability, as various for a period of six months, rhGH day^{-1} affects mean serum IGF-I factors, for which adjustments are not achievable.

CONCLUSION

However, the concentration (but not the predicted availability) was slightly lower. At first, the method of admission of GH released into the bloodstream affects the plasma half-life, notably) in contrast to that in the healthy control group, arguing that higher dosages of GH and rhGH are necessary. An intravenous bolus results in a shorter half-life Higher mean GH concentrations are needed than those that result from a steady GH infusion. Yes, it is abnormal IGF-I levels in the serum. Recent research indicates that it is likely that the GH metabolism clearance rate.

REFERENCES

1. Mardh G, et al. Growth hormone replacement therapy in adult hypopituitary patients with growth hormone deficiency: combined data from 12 European placebo-controlled clinical trials. Endocrinol Metab. 1994;1:43-49.
2. Jorgensen JO, et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet. 1989;333:1221-1225.
3. Cuneo RC, et al. The growth hormone deficiency syndrome in adults. Clin Endocrinol. 1992;37:387-397.
4. Bengtsson BA, et al. Treatment of adult with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab. 1993;76:309–317.
5. de Boer H, et al. Clinical aspects of growth hormone deficiency in adults. Endocr Rev. 1995;16:63-86.
6. Janssen YJ, et al. A low starting dose of genotropin in growth hormone-deficient adults. J Clin Endocrinol Metab. 1997;82:129-135.
7. Jørgensen JO, et al. Subcutaneous degradation of biosynthetic human growth hormone in growth hormone deficient patients. Eur J Endocrinol. 1988;118:154-158.
8. Salomon F, et al. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med. 1989;321:1797-1803.
9. Laursen T, et al. Bioavailability and bioactivity of intravenous vs subcutaneous infusion of growth hormone in GH-deficient patients. Clin Endocrinol. 1996;45:333-339.
10. du BOIS D. Clinical calorimeter. A formula to estimate the approximate surface if height and weight be known. Arch Intern Med. 1916;17:963-971.
11. Janssen YJ, et al. Using dilution techniques and multifrequency bioelectrical impedance to assess both total body water and extracellular water at baseline and during recombinant human growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab. 1997;82:3349-3355.
12. Jansson JO, et al. Effect of frequency of growth hormone administration on longitudinal bone growth and body weight in hypophysectomized rats. Acta Physiol Scand. 1982;114:261-265.
13. Clark RG, et al. Intravenous growth hormone: growth responses to patterned infusions in hypophysectomized rats. J Endocrinol. 1985;104:53-61.
14. Isgaard J, et al. Pulsatile intravenous growth hormone (GH) infusion to hypophysectomized rats increases insulin-like growth factor I messenger ribonucleic acid in skeletal tissues more effectively than continuous GH infusion. Endocrinology. 1988;123:2605-2610.
15. Jorgensen JO, et al. Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices. J Clin Endocrinol Metab. 1990;70:1616-1623.
16. Holl RW, et al. Diurnal variation in the elimination rate of human growth hormone (GH): the half-life of serum GH is

prolonged in the evening, and affected by the source of the hormone, as well as by body size and serum estradiol. J Clin Endocrinol Metabo. 1993;77:216-220.

17. Vahl N, et al. Bioavailability of recombinant human growth hormone in different concentrations and formulations. Pharmacol Toxicol. 1996;79:144–149.